Form 4: Indaptus Therapeutics Officer Acquires 75,000 Stock Options
SEC Form 4 Filing
Roger J. Waltzman, Chief Medical Officer of Indaptus Therapeutics, acquired 75,000 stock options on October 9, 2024.
Summary
- On October 9, 2024, Roger J. Waltzman, the Chief Medical Officer of Indaptus Therapeutics, Inc. (INDP), acquired 75,000 stock options.
- The options have an exercise price of $1.105.
- The stock options vest fully on April 9, 2026, contingent upon Waltzman's continued service to the company.
Sentiment
Score: 7
Explanation: The document is a routine disclosure of stock option grants, which is generally viewed as a neutral to slightly positive event as it aligns management incentives with shareholder value.
Positives
- The acquisition of stock options by a key officer aligns their interests with those of the shareholders.
Future Outlook
The vesting of the options is contingent upon the Reporting Person's continued service to the Issuer through the vesting date.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders by incentivizing them to increase the company's stock value.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead, and Biogen routinely use stock options to incentivize their executives.
- The size of the grant (75,000 options) would need to be compared to grants made to similarly positioned executives at comparable companies to determine if it is in line with industry standards.
Stakeholder Impact
- Shareholders may view the option grant positively as it incentivizes the Chief Medical Officer to work towards increasing the company's value.
- The Chief Medical Officer is incentivized to remain with the company through the vesting date.
Key Dates
| Date | Description |
|---|---|
| 10/09/2024 | Date of transaction: Roger J. Waltzman acquired 75,000 stock options. |
| 10/09/2024 | Date of grant: Stock options granted with an exercise price of $1.105. |
| 04/09/2026 | Vesting date: Stock options vest fully, subject to continued service. |
| 10/09/2034 | Expiration date: Stock options expire. |
| 10/10/2024 | Date of signature: Form 4 signed by Attorney-in-Fact for Roger J. Waltzman. |
Keywords
stock options, Indaptus Therapeutics, INDP, Roger J. Waltzman, Chief Medical Officer, Form 4, beneficial ownership, securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.